<?xml version="1.0" encoding="UTF-8"?>
<abstract abstract-type="author-highlights" id="ab0010">
 <title>Highlights</title>
 <p>
  <list list-type="simple" id="l0005">
   <list-item id="li0005">
    <label>•</label>
    <p id="p0005">Coronavirus disease 19 (COVID-19) is an emerging viral threat with major repercussions for public health.</p>
   </list-item>
   <list-item id="li0010">
    <label>•</label>
    <p id="p0010">There is not specific treatment for COVID-19.</p>
   </list-item>
   <list-item id="li0015">
    <label>•</label>
    <p id="p0015">Convalescent plasma (CP) emerges as the first option of management for hospitalized patients with COVID-19.</p>
   </list-item>
   <list-item id="li0020">
    <label>•</label>
    <p id="p0020">Transference of neutralizing antibodies helps to control COVID-19 infection and modulates inflammatory response.</p>
   </list-item>
   <list-item id="li0025">
    <label>•</label>
    <p id="p0025">Other plasma components may enhance the antiviral and anti-inflammatory properties of CP.</p>
   </list-item>
  </list>
 </p>
</abstract>
